Highlights

  • Nanosonics (ASX:NAN) reported FY26 revenue of AUD 203.9 million, up 2.7%.
  • The worldwide installed base of trophon devices reached 39,230 in FY26.
  • FY26 earnings before interest and tax were AUD 16.0 million.
  • CORIS commercialisation is planned across regions during FY27.

Nanosonics Limited develops medical-device reprocessing technologies used by healthcare providers, including the trophon ultrasound-probe disinfection platform and the CORIS flexible-endoscope cleaning system. Its latest financial results and preparations for CORIS commercialisation place product adoption and operating expenditure in focus. On 20 October 2026, Nanosonics Limited (ASX:NAN) shares were quoted at AUD 3.01, up 1.35% for the trading session, according to the stated market figures.

Company Business

The company supplies automated infection-prevention equipment, consumables, software and related services. Its established trophon platform provides high-level disinfection for ultrasound probes using hydrogen peroxide technology. Alongside equipment placements and upgrades, recurring sales arise from consumables and service arrangements supporting devices already in use.

The CORIS System addresses a different procedure: cleaning the internal channels of flexible endoscopes before subsequent disinfection. This broadens the company’s product scope beyond ultrasound probe reprocessing. For Nanosonics (ASX:NAN), commercial execution across two technology platforms is therefore an important operational distinction.

Recent Development

In August 2026, the company reported that worldwide trophon placements reached 4,230 devices during FY26, an increase of 9% from the preceding reporting period. Its cumulative installed base expanded 6% to 39,230 devices. North American upgrades increased 32%, reflecting activity within the existing installed population as well as new placements.

The company also reported progress with the CORIS controlled market release. Its FY26 annual report described regulatory clearances in Australia, Europe and the United Kingdom, together with expanded endoscope indications cleared by the US Food and Drug Administration. Further submissions for additional endoscope indications were underway. Nanosonics (ASX:NAN) planned a phased commercial launch across regions during FY27, with initial CORIS revenue anticipated during that financial year.

The proposed launch represents a change from controlled deployments to wider commercial activity. The extent and timing of adoption remain dependent on customer readiness, clinical integration, training, manufacturing capacity and applicable regulatory permissions.

Financial Performance and Sector Context

For the year ended 30 June 2026, Nanosonics reported revenue of AUD 203.9 million, representing a 2.7% year-on-year increase. At constant currency, revenue was AUD 211.5 million, reflecting the effect of exchange-rate movements on reported results. The comparison illustrates why reported and constant-currency figures should be distinguished when assessing international healthcare suppliers.

Earnings before interest and tax were AUD 16.0 million, down 10.2%, while profit before tax was AUD 20.1 million. Net profit attributable to shareholders amounted to AUD 17.8 million, down 13.7%. The trophon-only business generated AUD 50.6 million in earnings before interest and tax; this management measure excludes investment attributable to the CORIS programme and should not be confused with group EBIT.

At 30 June 2026, cash and cash equivalents stood at AUD 155.2 million, and the company reported no debt. Its FY26 results also noted completion of an AUD 20 million buyback and announced a further on-market buyback of up to AUD 40 million for FY27. Nanosonics (ASX:NAN) must balance product development expenditure, manufacturing requirements and shareholder capital returns within that financial position.

Hospital infection-prevention standards, validation requirements and procurement budgets shape the sector in which the company operates. Healthcare facilities may evaluate equipment costs alongside reprocessing time, traceability, staffing requirements and consumables. International selling activity also exposes reported performance to currency movements and trade-related costs.

Risks to Consider

The planned CORIS rollout carries launch, regulatory, manufacturing and customer-adoption risks. A controlled release does not establish the pace of broader purchasing or repeat consumables demand. Operating expenditure could rise ahead of revenue from a newly commercialised platform. Currency movements and supply-chain conditions may also influence margins and financial comparisons.

What to Watch Next

The next reporting periods may provide more detail on CORIS launch sequencing, initial sales, regulatory expansion and customer deployments. Changes in trophon placements, upgrades and recurring revenue will help distinguish installed-base expansion from consumption within the existing fleet.

Investors may also monitor group expenditure, gross margin, cash balances and the execution of the announced buyback. Future ASX releases should clarify whether milestones are reached and how investment in the two product platforms is reflected in operating results.

Key Insights

Nanosonics enters FY27 with an established trophon installed base, reported FY26 revenue of AUD 203.9 million and a CORIS launch programme moving beyond controlled release. Group EBIT decreased on a reported basis, while cash resources remained material to its development and commercial activities. The principal measurable developments for Nanosonics (ASX:NAN) are device adoption, recurring revenue, CORIS milestones and the costs associated with scaling operations.